Correlation Between Ikena Oncology and Milestone Pharmaceuticals

Can any of the company-specific risk be diversified away by investing in both Ikena Oncology and Milestone Pharmaceuticals at the same time? Although using a correlation coefficient on its own may not help to predict future stock returns, this module helps to understand the diversifiable risk of combining Ikena Oncology and Milestone Pharmaceuticals into the same portfolio, which is an essential part of the fundamental portfolio management process.

By analyzing existing cross correlation between Ikena Oncology and Milestone Pharmaceuticals, you can compare the effects of market volatilities on Ikena Oncology and Milestone Pharmaceuticals and check how they will diversify away market risk if combined in the same portfolio for a given time horizon. You can also utilize pair trading strategies of matching a long position in Ikena Oncology with a short position of Milestone Pharmaceuticals. Check out your portfolio center. Please also check ongoing floating volatility patterns of Ikena Oncology and Milestone Pharmaceuticals.

Diversification Opportunities for Ikena Oncology and Milestone Pharmaceuticals

0.41

Correlation Coefficient

Ikena Oncology  Milestone Pharmaceuticals

Very weak diversification

The 3 months correlation between Ikena and Milestone is 0.41. Overlapping area represents the amount of risk that can be diversified away by holding Ikena Oncology and Milestone Pharmaceuticals in the same portfolio, assuming nothing else is changed. The correlation between historical prices or returns on Milestone Pharmaceuticals and Ikena Oncology is a relative statistical measure of the degree to which these equity instruments tend to move together. The correlation coefficient measures the extent to which returns on Ikena Oncology are associated (or correlated) with Milestone Pharmaceuticals. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when the price movement of Milestone Pharmaceuticals has no effect on the direction of Ikena Oncology i.e., Ikena Oncology and Milestone Pharmaceuticals go up and down completely randomly.

Pair Corralation between Ikena Oncology and Milestone Pharmaceuticals

Given the investment horizon of 90 days Ikena Oncology is expected to generate 0.23 times more return on investment than Milestone Pharmaceuticals. However, Ikena Oncology is 4.27 times less risky than Milestone Pharmaceuticals. It trades about -0.12 of its potential returns per unit of risk. Milestone Pharmaceuticals is currently generating about -0.09 per unit of risk. If you would invest  160.00  in Ikena Oncology on December 29, 2024 and sell it today you would lose (27.00) from holding Ikena Oncology or give up 16.87% of portfolio value over 90 days.

Time Period	3 Months [change]
Direction	Moves Together
Strength	Weak
Accuracy	100.0%
Values	Daily Returns

Ikena Oncology  vs.  Milestone Pharmaceuticals

Ikena Oncology

Risk-Adjusted Performance

Very Weak

Over the last 90 days Ikena Oncology has generated negative risk-adjusted returns adding no value to investors with long positions. Despite weak performance in the last few months, the Stock's basic indicators remain somewhat strong which may send shares a bit higher in April 2025. The current disturbance may also be a sign of long term up-swing for the company investors.

Milestone Pharmaceuticals

Risk-Adjusted Performance

Very Weak

Over the last 90 days Milestone Pharmaceuticals has generated negative risk-adjusted returns adding no value to investors with long positions. In spite of unsteady performance in the last few months, the Stock's basic indicators remain comparatively stable which may send shares a bit higher in April 2025. The newest uproar may also be a sign of mid-term up-swing for the firm private investors.

Pair Trading with Ikena Oncology and Milestone Pharmaceuticals

The main advantage of trading using opposite Ikena Oncology and Milestone Pharmaceuticals positions is that it hedges away some unsystematic risk. Because of two separate transactions, even if Ikena Oncology position performs unexpectedly, Milestone Pharmaceuticals can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Milestone Pharmaceuticals will offset losses from the drop in Milestone Pharmaceuticals' long position.

The idea behind Ikena Oncology and Milestone Pharmaceuticals pairs trading is to make the combined position market-neutral, meaning the overall market's direction will not affect its win or loss (or potential downside or upside). This can be achieved by designing a pairs trade with two highly correlated stocks or equities that operate in a similar space or sector, making it possible to obtain profits through simple and relatively low-risk investment.

Check out your portfolio center.

Note that this page's information should be used as a complementary analysis to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the Commodity Channel module to use Commodity Channel Index to analyze current equity momentum.